ERBB2 and colorectal carcinoma: Furthermore, an immunocompetent Balb/c mouse model was established by using murine colorectal carcinoma CT26 cells stably expressing human HER2 (CT26.WT‐hHER2) to investigate the in vivo efficacy of HER2‐ICG in combination with systemic PD‐1 antibodies (Figure 6E).